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Microsponges are polymeric microsphere delivery 
systems. They are small sponge-like spherical 
particles which have a large porous surface. Porous 
microspheres with a size range between 5 and 300 
microns depending on the degree of smoothness or 
the feeling necessary for the final formulations. They 
may also improve stability, reduce side effects, and 
favorably Change drug release. Microsponge 
technology has many favorable characteristics, which 
make it a versatile drug delivery vehicle. 
Microsponge systems are based on microscopic, 
polymer-based microspheres that can suspend or trap 
a broad range of substances and can then be 
integrated into a formulated product such as gel, 
cream, liquid or powder. The outer surface is 
typically porous, allowing a sustained flow of 
substances out of the sphere. Appropriate analytical 
methods are discussed for characterizing 
microsponges such as particle size and distribution, 
surface morphology, porosity, and density. 
Microsponges are designed to deliver a 
pharmaceutically active ingredient efficiently at the 
minimum dose and also to enhance stability, reduce 
side effects, and modify drug release. 
 
Keywords: Controlled release, distribution of drugs, 




In recent years, it has become more and 
more evident that the development of new 
drugs alone is not sufficient to ensure 
progress is drug therapy. A promising 
strategy involves the development of a 
suitable drug carrier system. In-vivo 
destiny is determined not only by the 
drug's characteristics but also by the 
carrier system, which allows the active 
drug to be released controlled and located 
according to the particular treatment needs 
[1]. Microsponges are polymeric delivery 
systems composed of porous 
microspheres. They are tiny sponge-like 
spherical particles with a large porous 
surface. Moreover, they may enhance 
stability, reduce side effects, and 
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advantageously change the release of 
drugs. Microsponge technology has many 
favourable characteristics, which make it a 
versatile drug delivery vehicle. 
Microsponge systems are based on 
microscopic, polymer based microspheres 
that can suspend or trap a broad range of 
substance and can then be integrated into a 
formulated product such as gel, cream, fluid 
or powder [2−4]. The Microsponge 
Delivery System (MDS) is a patented 
polymeric system consisting of porous 
microspheres. They are small sponge-like 
spherical particles consisting of a 
multitude of interconnecting voids within a 
non-collapsible framework with a big 
porous surface through which the active 
ingredient is released in a controlled way. 
Microsponges are stable over a range of 
pH 1-11 and temperature up to 130°C and 
are compatible with most vehicles and 
ingredients, and self-sterilizing since their 
average pore size is 0.25 μm where 
bacteria cannot penetrate these 
formulations are free-flowing and can be 
cost-effective [5−7]. Microsponges 
methods are used to improve the efficiency 
of topically applied drugs to solve 
problems such as greasiness, topical 
formulations-related stickiness [8, 9]. 
 
MDS can efficiently provide enhanced 
efficacy for topically active agents with 
enhanced safety, increased product 
stability, and enhanced aesthetic properties 
[2−4]. To control the delivery rate of active 
agents to a predetermined site in the human 
body has been one of the biggest challenges 
faced by Pharmaceutical scientists. Several 
predictable and reliable schemes have been 
created for the systemic transmission of 
drugs under the heading of the transdermal 
delivery system (TDS) using the skin as an 
entry point. It has improved the efficacy 
and safety of many drugs that may be better 
administered through the skin. But TDS is 
not practicable for delivery of materials 
whose final target is skin itself. Controlled 
release of drugs onto the epidermis with an 
assurance that the drug Remains primarily 
located and does not enter significant 
amounts of the systemic circulation is a 
challenging area of research [10]. 
Microsponges consist of non-collapsible 
structures with the porous surface through 
which active ingredients are released in a 
controlled manner. Depending upon the 
size, the total pore length may range up to 
10 ft. and pore volume up to 1 ml/g. When 
applied to the skin, the microsponge drug 
delivery system (MDS) releases its active 
ingredient on a time mode and also in 
response to other stimuli such as rubbing, 
temperature, and pH Microsponges can 
adsorb or load a high degree of active 
materials into the particle or onto its 
surface. Its large magnitude for entrapment 
of actives up to 3 times its weight 
differentiates microsponges from other 
types of dermatological delivery systems. 
Mostly microsponge is used as a 
transdermal drug delivery system [11, 12]. 
 
History of Microsponge 
Won developed the microsponge 
technology in 1987, [13, 14] and assigned 
the original patents to Advanced Polymer 
Systems, Inc. This company developed a 
large number of variations of the 
procedures, and those are applied to the 
cosmetic as well as over-the-counter 
(OTC) and prescription pharmaceutical 
products. Currently, this interesting 
technology has been licensed to Cardinal 
Health, Inc. for use in topical goods. 
 
Structure of Microsponge 
The size of the microsponges may vary 
depending on the degree of smoothness or 
after-feel required for the end formula, 
usually from 5 to 300 μm in diameter. 
Even though the size of the microsponge 
varies, a typical 25 μm [15] sphere can 
have up to 250000 pores and an internal 
pore structure equivalent to 10 ft. in 
length, providing a total pore volume of 
about 1 ml/g. This results in a large 
reservoir within each microsponge, which 
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can be loaded with up to the weight of the 
active agent. The microsponge particles 
themselves are too large to be absorbed 
into the skin, and this adds a measure of 
safety to these microsponge materials. The 
potential bacterial contamination of the 
materials trapped in the microsponge is 
another safety concern. Due to the smaller 
size of the pore diameter, the bacteria 
ranging from 0.007 to 0.2 μm cannot 
penetrate the microsponges ' tunnel 
structure. The release of active ingredients 
from conventional topical formulation 
over an extended period is quite difficult. 
These vehicles high concentration of 
active agents for effective therapy because 
of their low efficacy of the delivery 
system, resulting in irritation and allergic 
reaction in significant users. Microsponge 
technology, on the other hand, enables an 
even and sustained release rate, lowering 
irritation while retaining effectiveness. 
Their elevated degree of cross-linking 
outcomes in insoluble, inert particles of 
adequate strength to withstand the heavy 
shear that is widely used in cream, lotion, 
and powder manufacturing [16]. 
 
Their distinctive feature is the ability to 
adsorb or "load" into and on the particles a 
large degree of active material. Its large 
capacity for entrapment of actives, up to 
three times its weight, distinguishes 
microsponge products from other types of 




 The formulations of microsponge are 
stable over the pH 1 to 11 spectrum 
[17]. 
 It is stable at the temperature up to 
130°C. 
 They are compatible with most 
vehicles and ingredients. 
 They are self-sterilizing because they 
have an average pore size of 0.25μm 
where bacteria cannot penetrate. 
 Microsponge formulations have high 
entrapment of up to 50 to 60%. 
 It is free-flowing and can be cost-
effectively reduced irritation and hence 
improved patient compliance. 
 
Microsponges must meet the following 
requirements  
 If the drug is typically non-polar 
material; it should create the porous 
structure this is called porogen [18].  
 Immiscible or at most only mildly 
soluble water should be available.  
 Monomers and polymers should be 
inert. 
 Polymerization catalyst contact and 
polymerization conditions should be 
stable.  
 A release can be regulated by diffusion 
or other causes such as moisture, pH, 
friction or temperature. 
 
Method of Preparation of Microsponges  
Based on the physicochemical 
characteristics of the drug to be integrated 
into the microsponge, this is split into two 
aspects [19, 20], 
1. One-step process or liquid-liquid 
suspension polymerization. 





In this method, the monomers are first 
dissolved together with active ingredients 
in a suitable monomer solvent solution and 
then dispersed with agitation in the 
aqueous phase. Aqueous phase typically 
consists of addictive’s such as surfactants 
and dispersants (suspending agent) etc. to 
facilitate the formation of suspension. 
Once the suspension is formed with 
separate droplets of the desired size, 
polymerization is launched either by 
adding a catalyst or by raising temperature 
and irradiation [21]. The technique of 
polymerization contributes to the growth 
of a system type reservoir that opens 
through pores at the ground. In some 
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cases, however, a completely miscible 
inert liquid with water is used to form the 
pore network during polymerization. Once 
the polymerization process is complete, 
the aqueous is removed, leaving the 
microsponges permeated in pre-formed 
microsponges, incorporating the variety of 
active substances such as antifungal, anti-
acne, anti-inflammatory, etc., and acting as 
topical carriers [22]. 
 
 
Figure 1: Liquid-liquid suspension polymerization. 
 
The different steps engaged in 
microsponge preparing are summarized 
as follows [23] 
Step1: Selection of monomers and 
combination of monomers. 
Step2: Formation of chain monomers as 
polymerization starts. 
Step3: Formation of ladders as a result of 
cross-linking between chain monomers.  
Step4: Folding of the monomer ladder to 
form spherical particles. 
Step5: Agglomeration of microsphere 
leads to the production of bunches of 
microspheres. 
Step6. Binding of clusters to produce 
microsponges. 
 
Quasi–emulsion solvent diffusion 
The two-step method is used when the 
drug is susceptible to the circumstances of 
polymerization. Microsponges are 
prepared using the various polymer 
quantities using a technique of quasi-
emulsion solvent diffusion [24]. The 
affinity between the drug and the good 
solvent is stronger in emulsion solvent 
diffusion than that of the excellent solvent 
and the poor firm. The drug is dissolved in 
the healthy solid and the solution is spread 
into the bad firm, creating emulsion 
droplets, although the natural solvents are 
miscible. The healthy solvent gradually 
diffuses into the bad solvent stage from the 
emulsion particles and the bad solvent 
spreads into the droplets inside the cells by 
which the drug crystallizes. This is a two-
step process in which the polymer is 
poured into an external aqueous phase, 
typically consisting of a stabilizer such as 
polyvinyl alcohol, along with the active, 
plasticizer and diffusible substance 
(Porogen). The system is continuously 
stirred for 2 hours after emulsification and 
maintained at an elevated temperature if 
necessary. An extremely porous 
microparticle called 'Microsponge' results 
in the diffusion of porogen into the 
external medium. Then, to separate the 
microsponges, the mixture is filtered. The 
product has been washed and dried for 24 
hours in a vacuum oven at 50°C [25].
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Figure: 2: Preparation of microsponges by quasi-emulsion solvent diffusion method. 
 
Microsponges Release Mechanisms 
MDS comprises of a variety of porous 
microspheres containing a complex 
network of interconnecting voids with a 
non-collapsible framework. Depending on 
several modifiable variables, the rate of 
discharge of the active components can be 
determined before they are trapped in the 
microsphere. These modifiable factors 
include the pore diameter, the extent of 
polymer cross-linking, the difference 
between the microspheres in the 
concentration of the active ingredient and 
the vehicle in which these spheres reside. 
It is possible to prepare the topical agent 
formulation with MDS in many different 
forms, such as gel, cream, or lotion. Once 
the formulation is applied topically to the 
desired skin area, the active ingredients 
spread to the vehicle from the spheres and 
then to the skin. Microsponges can be 
designed in response to one or more 
external triggers to release a given amount 
of active ingredients over time [26]. 
 
Pressure Triggered Systems 
When pressurized/rubbed, the 
microsponge scheme releases the trapped 
material; the quantity produced relies on 
the sponge's different features [27]. The 
microsponge best suited for a specified 
implementation can be optimized by 
changing the fabric sort and distinct 
system factors. Compared to mineral oil 
comprising microcapsules, there was a 
much more softening impact of mineral oil 
containing microsponge. For the 
microsponge systems, the duration of 
emolliency was also much more. 
 
Temperature Triggered Systems 
At room temperature, some trapped active 
ingredients may be too viscous to flow 
spontaneously from microsponges to the 
skin [40]. Increased skin temperature can 
lead to increased flow rate and therefore 
release. Thus, the release of substances 
from the microsponge can be modulated 
through temperature modulation. For 
example, when exposed to higher 
temperatures, viscous sunscreens showed a 
higher release from microsponges; thus, a 
sunscreen would only be released from a 
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pH Triggered Systems Triggering 
The active's pH-based discharge can be 
accomplished by altering the microsponge 
layer. This has many medication delivery 
applications [39]. 
 
Solubility Triggered System 
In the presence of water, microsponges 
packed with water-soluble components 
such as antiperspirants and antiseptics 
discharge the product [41]. The presence 
of an aqueous medium such as suddenness 
can cause the active ingredient discharge 
frequency. Thus discharge can be 
accomplished depending on the capacity of 
the internal medium to absorb the active, 
the gradient of concentration or the 
capacity to expand the network of 
microspore.  
 
EVALUATION METHODOLOGY OF 
MICROSPONGE 
In vitro techniques  
Particle Size and Size Distribution 
Particle size and distribution of size are 
assessed using either an optical 
microscope or an electron microscope. 
This is an extremely important step as the 
particle size greatly affects the texture and 
stability of the formulation. Free-flowing 
powders with good aesthetic 
characteristics can be obtained by 
regulating the particle size during 
polymerization. Particle size assessment of 
charged and unloaded microsponges can 
be conducted using laser light 
diffractometer or any other appropriate 
technique. The values (d50) can be 
expressed as the mean size range for all 
formulations. To study the effect of 
particle size on drug release, cumulative 
percentage drug release from 
microsponges of different particle sizes 
will be plotted against time [28]. 
 
Morphology and Surface Topography of 
SPM 
Various methods such as photon 
correlation spectroscopy (PCS), scanning 
electron microscopy (SEM), transfer 
electron microscopy (TEM), etc. have 
been used for morphology and surface 
topography. SEM is commonly used for 
which prepared microsponges are covered 
with gold-palladium at room temperature 
under an argon environment and then the 
surface structure of the microsponges is 
studied [29]. 
 
Determination of Loading Efficiency 
and Production Yield 
The loading efficiency (percentage) of the 
microsponges can be calculated using the 
following equation: 
                    
 
                                   
                        
       
 
The production yield of the microparticles 
can be determined by accurately 
calculating the initial weight of the raw 
materials and obtaining the last weight of 
the SPM [30].  
                  
                                           
            
 
Determination of True Density 
The real density of microsponges can be 
evaluated using an ultra-pycnometer under 
helium gas and is calculated from an 
average of repeated determinations [29]. 
 
Characterization of Pore Structure  
Pore volume and diameter are essential for 
controlling the active ingredient's intensity 
and duration of efficacy. Pore diameter 
also affects the migration of active 
ingredients from microsponges to the 
vehicle that disperses the material. 
Mercury porosimetry intrusion may be 
used to explore the impact of pore 
diameter and quantity with Microsponges 
substance discharge frequency. 
Microsponges porosity parameters include 
intrusion– isotherms of extrusion. By 
using mercury intrusion porosimetry, the 
allocation of pores, total surface area of 
the pore, average pore diameters, pores 
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shape and morphology, volume and 
relative density can be determined. 
  
Incremental bulk intrusion scanning is 
mapped against pore diameters 
representing distributions of pore size. 
Microsponges pore diameter can be 
calculated using the equation Washburn 
[31, 32]: 
             
Where, D is the pore diameter (μm); γ the 
surface tension of mercury (485 dyn 
cm−1); θ he contacts angle (130o), and P 
is the pressure (psi).  
The total area of the pores (Atot) was 
calculated using equation, 
                         
Where, P is the pressure (psi); V is the 
volume (mL g−1); Vtot is the total specific 
intrusion volume (mL g−1). The average 
pore diameter (Dm) was calculated by 
using equation, 
              
Envelope (bulk) density (ρse) of the 
Microsponges was calculated by using 
equation,  
        ⁄      
Where, Ws is the weight of the SPM 
sample (g); Vp the empty penetrometer 
(mL); VHg is the volume of mercury 
(mL). Absolute (skeletal) density (ñsa) of 
Microsponges was calculated by using 
equation,  
                 
 
Where, Vse is the volume of the 
penetrometer minus the volume of the 
mercury (mL). Finally, the % porosity of 
the sample was found from the equation, 
  
           (
      
    
)      
Pore morphology can be characterized by 
the intrusion– extrusion profiles of 
mercury in the Microsponges. 
 
Compatibility Studies 
Compatibility studies of drug-excipients 
are performed to ensure that when 
formulated in a dosage form, there is no 
inadvertent reaction between the two. 
These tests are frequently performed by 
recording the differential Calorimetry 
(DSC) screening of the chemicals viz., 
APIs and excipients separately and 
together as well as searching for any 
increase or removal of any peaks or 
troughs. For DSC, roughly 5 mg 
specimens can be precisely weighed and 
locked into aluminum pans and operated at 
a boiling speed of 15oC / min over a 
temperature spectrum of 25–430oC in the 
nitrogen atmosphere.[33, 34] Infrared (IR) 
testing may also disclose the 
incompatibilities between chemical 
molecules. Thin-layer chromatography 
(TLC) and FT-IR [35] may also study drug 
compatibility with reaction adjuncts. 
Powder X-ray diffraction (XRD) and 
Differential Scanning Colorimetry (DSC) 
can be used to study the effect of 
polymerization on drug crystallinity [36].  
 
Polymer/Monomer Composition  
The drug discharge from Microsponges is 
governed by factors such as particle size, 
drug charging, and polymer structure. The 
Microsponges Drug Delivery system's 
polymer structure can affect the partition 
coefficient of the trapped drug between the 
vehicle and the Microsponges system, thus 
directly affecting the discharge frequency 
of the trapped drug.  
 
Drug discharge from microsponge 
structures of various polymer structures 
can be explored by plotting against time 
cumulative percent discharge of drugs. 
The speed of release and complete 
quantity of drugs produced from the 
methane methacrylate/ethylene glycol 
dimethacrylate structure is smaller than the 
process of styrene/divinylbenzene. 
Monomer selection is influenced by both 
the trapping features of the active 
ingredient and the vehicle into which it 
will be distributed. Polymers with variable 
electrical costs or degrees of 
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hydrophobicity or lipophilicity may be 
ready to make active ingredient releases 
flexible. Different monomer mixes will be 
tested by analysing their drug discharge 




Microsponges' resilience (viscoelastic 
characteristics) can be altered to create 
weaker or firmer beadlets, depending on 
the initial formulation requirements. 
Higher cross-linking tends to slow the 
discharge rate. Therefore, Microsponges ' 
resilience is researched and optimized 
according to the necessity by considering 





Microsponges dissolution discharge 
frequency can be researched using the 
USP XXIII dissolution device with a 
customized container of 5μm stainless 
metal mesh. The speed of the rotation is 
150 rpm. The dissolution medium is 
selected while considering the solubility of 
actives to ensure sink conditions. At 
various intervals, the samples from the 
dissolution medium were analyzed by 
suitable analytical methods [42]. 
 
Recent Advances in the Microsponge 
Drug Delivery System 
By changing the techniques to create 
nanosponges, nano-ferrosponges, and 
porous microbeads, various developments 
have been produced. In comparison to 
polymeric micro or nanosponges, β-CD 
nanosponges have also been created that 
can be used for both hydrophobic and 
hydrophilic drugs. These sophisticated 
structures have been researched as a model 
drug for oral administration of 
dexamethasone, flurbiprofen, 
hydrochloride doxorubicin, itraconazole, 
and serum albumin. Through re-acting the 
β-CD with diphenyl chloride, these 
nanosponges were created by cross-linking 
the β-CD molecule. The nanosponges were 
also noted by some scientists as a useful 
provider for gas distribution. Researchers 
also noted that integrating a cytotoxic into 
a nanosponge carrier system could boost 
the drug's potency, implying that these 
carriers could be used to target cancer cells 
[43].  
 
Nanoferrosponge, a novel method, formed 
the self-performing carriers with superior 
resistance to the target location owing to 
the internal magnetic mechanism that 
enables the carriers to pierce into the 
deepest tissue and then cause the particle 
to be removed from the magnetic material 
leaving a porous system [44]. 
 
Because of the improved characteristics of 
porous microspheres, the process to 
produce porous microbeads was 
developed. This method (High internal 
phase emulsion, HIPE) consisted of a 
monomer containing a continuous oil 
phase, interlinking agent and internal 
aqueous phase [45]. They also observed an 
enhanced RNA stability and SiRNA's 
relatively effective encapsulation process. 
The approach could lead to new 
therapeutic pathways for the delivery of 
siRNA [46].  
 
FUTURE PROSPECTS 
Microsponge drug delivery system offers 
promising opportunities soon in multiple 
pharmaceutical implementations as it has 
distinctive characteristics such as 
enhanced product quality and elegance, 
expanded release, enhanced drug release 
profile, decreased discomfort, enhanced 
physical, chemical, and thermal stability, 
making it easy to create new product 
types. 
  
The real role in the future is the design of 
the delivery system for oral peptide 
distribution by variable polymer ratio. The 
use of bioerodible and biodegradable 
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polymers for drug delivery enables it to 
deliver active content safely. Since these 
porous structures have also been 
researched for drug delivery through the 
pulmonary path, which demonstrates that 
these structures can demonstrate efficient 
drug discharge even in the scarcity of the 
dissolved fluid, the colon is an efficient 
destination location for drug discharge. 
These carriers also need to be established 
for alternative paths of drug administration 
such as parenteral and pulmonary 
pathways. These ions can also be used as 
the medium of cell culture and can 
therefore also be used in the environment 
for stem cell culture and tissue 
regeneration. These carrier systems have 
also found their application in cosmetics 
because of their elegance. These 
developments enabled researchers to make 
varying use of them. These novelties in the 
formulation also open up new ways of 
delivering drugs [47].  
 
CONCLUSION 
There is a very strong demand for fresh 
and very effective pharmaceutical and 
cosmetic products in the global sector. For 
Microsponge technology, the industry 
needs capacity and versatility. During 
formulation consideration, the formulator 
can understand the complete capacities of 
these distinctive products providing 
enhanced strength, enhanced safety, and 
reduced side effects from API, enhanced 
multi-functionality and improved 
compatibility of ingredients.  
 
Microsponge delivery system is a 
challenge for a fresh generation of 
pharmaceutical and cosmetic industries. 
Microsponges have a distinct benefit over 
the current standard topical dosage forms 
for the therapy of tropical diseases; it is a 
distinctive technology for the controlled 
release of topical agents also used for oral 
as well as biopharmaceutical drug 
delivery. This demonstrates an advantage 
over other products by non-mutagenic, 
non-toxic, non-irritant. So the 
microsponge drug delivery system has a 
lot of potentials and is a very emerging 
field that needs to be explored with the 
most research study in the future. 
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